Roche's Genentech Announces Topline Results From The Global Phase III BALATON And COMINO Studies, Evaluating Extended Vabysmo® Treatment Intervals For Macular Edema
Portfolio Pulse from Benzinga Newsdesk
Roche's Genentech has announced the topline results from its global Phase III BALATON and COMINO studies, which evaluated extended Vabysmo® treatment intervals for macular edema. The results of these studies could potentially impact the future use and sales of Vabysmo®.
October 10, 2023 | 6:46 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The results of the BALATON and COMINO studies could potentially impact the future use and sales of Roche's Vabysmo®, which would directly affect Roche's stock.
The results of these studies could potentially change the way Vabysmo® is used in the treatment of macular edema, which could either increase or decrease its sales. This would directly impact Roche's revenues and, consequently, its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
The results of the BALATON and COMINO studies could potentially impact the future use and sales of Roche's Vabysmo®, which would directly affect Roche's stock.
The results of these studies could potentially change the way Vabysmo® is used in the treatment of macular edema, which could either increase or decrease its sales. This would directly impact Roche's revenues and, consequently, its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100